
Eli Lilly and Company, Moderna, and Johnson & Johnson are the three Healthcare stocks to watch today, according to MarketBeat’s stock screener tool. Healthcare stocks are shares of publicly traded companies that provide healthcare products or services, such as pharmaceutical and biotechnology firms, medical-device makers, hospitals, and health insurers. Investors may buy them to gain exposure to the healthcare sector, whose performance can be shaped by medical innovation, regulation, and demand for care. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE:LLY traded up $2.98 on Monday, reaching $1,446.48. The company’s stock had a trading volume of 1,297,145 shares, compared to its average volume of 2,949,839. The company has a market cap of $1.36 trillion, a P/E ratio of 46.92, a PEG ratio of 1.73 and a beta of 0.40. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The company has a 50-day simple moving average of $1,242.25 and a 200 day simple moving average of $1,110.30.
Read Our Latest Research Report on LLY
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of NASDAQ:MRNA traded down $5.87 during trading on Monday, hitting $217.50. The company had a trading volume of 3,270,976 shares, compared to its average volume of 12,530,870. The stock has a market cap of $88.01 billion, a price-to-earnings ratio of -30.60 and a beta of 1.16. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. The company has a fifty day simple moving average of $201.67 and a two-hundred day simple moving average of $96.41. Moderna has a one year low of $22.28 and a one year high of $280.80.
Read Our Latest Research Report on MRNA
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
NYSE JNJ traded down $0.65 on Monday, hitting $285.10. 2,379,985 shares of the stock were exchanged, compared to its average volume of 7,927,020. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a 52-week low of $195.90 and a 52-week high of $290.25. The firm has a market capitalization of $686.31 billion, a P/E ratio of 43.22, a P/E/G ratio of 2.82 and a beta of 0.22. The stock has a fifty day moving average price of $266.97 and a two-hundred day moving average price of $249.85.
Read Our Latest Research Report on JNJ
Read More
- MarketBeat’s Top Five Stocks to Own in November 2026
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
